- Federal government must find alternatives to rescheduling hydrocodone combination drugs
- Prestige Brands solution to pediatric overdosing — unique squeezable, single-dose APAP packet
- CVS Caremark study: More education needed on genetic testing in prescribing antiplatelet drugs
- Pharmagen launches Warfarin-friendly multivitamin
- Soluble Oat Bran
LAVAL, Quebec — Valeant Pharmaceuticals on Tuesday announced it has completed its previously announced acquisition of Bausch + Lomb.
Bausch + Lomb is a global eye health company that has a broad portfolio of eye health products, including well-known prescription and OTC brands Besivance, Lotemax, Ocuvite and PreserVision; vision care brands Biotrue ONEday, PureVision, renu and Boston; and surgical brands enVista, Storz, Stellaris and Victus.
Valeant started the process in May, when it announced the all-cash $8.7 billion acquisition. The move will make Valeant one of the leaders worldwide across both dermatology and eye health, the company said.
Like this story? Find us on Facebook for more insight, analysis and the latest in drug store news. Join the conversation.